Department of Ophthalmology, Albany Medical College, Albany, NY; and.
Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD.
Cornea. 2024 Aug 1;43(8):982-988. doi: 10.1097/ICO.0000000000003489. Epub 2024 Feb 2.
The aim of this study was to report long-term outcomes of patients who have undergone Boston type I keratoprosthesis (KPro) surgery.
This study was a retrospective review. Inclusion criteria were KPro surgery between 2006 and 2012 and at least 10 years of follow-up. Demographics, ocular history, surgery indication, clinical variables, and postsurgical outcomes were recorded. Descriptive statistical analysis was performed.
We identified 75 patients with KPro implantation, and 17 patients with at least 10 years of follow-up (median = 11.1 years; range, 10.0-12.8 years) were included. Of 17 eyes, 11 (64.8%) had their original device in situ, 3 (17.6%) had their second device in situ, 1 (5.9%) had the device removed and replaced with a donor keratoplasty, and 2 (11.8%) were enucleated. At the last follow-up, 11 eyes (64.7%) were able to maintain improvement in vision, 5 (29.4%) had worsened vision, 1 (5.9%) had stable vision, and 9 (52.9%) had visual acuity <Snellen 20/200. Major complications included infectious keratitis (n = 5, 29.4%), hypotony (n = 4, 23.5%), retinal detachment (n = 4, 23.5%), endophthalmitis (n = 2, 11.8%), and retroprosthetic membrane (n = 7, 50%). In addition, 15 eyes (88.2%) required glaucoma surgery. All but 1 eye lost best-ever visual acuity with 9 eyes (52.9%) because of glaucoma progression.
KPro had an acceptable retention proportion and remains a viable option for eyes at high risk of failure with donor keratoplasty. However, subsequent surgeries are commonly performed postoperatively to manage complications. Glaucoma seems to be the main etiology of irreversible vision loss.
本研究旨在报告接受波士顿 I 型角膜假体(KPro)手术的患者的长期结果。
本研究为回顾性研究。纳入标准为 2006 年至 2012 年间行 KPro 手术且随访时间至少 10 年。记录患者的人口统计学、眼部病史、手术适应证、临床变量和术后结果。采用描述性统计分析。
共纳入 75 例行 KPro 植入术的患者,其中 17 例(17 眼)随访时间至少 10 年(中位数=11.1 年;范围 10.0-12.8 年)。17 眼中,11 眼(64.8%)原植入物在位,3 眼(17.6%)第二植入物在位,1 眼(5.9%)原植入物取出并更换为供体角膜移植,2 眼(11.8%)眼球摘除。末次随访时,11 眼(64.7%)视力改善,5 眼(29.4%)视力恶化,1 眼(5.9%)视力稳定,9 眼(52.9%)视力<Snellen 20/200。主要并发症包括感染性角膜炎(5 眼,29.4%)、低眼压(4 眼,23.5%)、视网膜脱离(4 眼,23.5%)、眼内炎(2 眼,11.8%)和后发性角膜混浊(7 眼,50%)。此外,15 眼(88.2%)需行青光眼手术。除 1 例外,所有患者最佳矫正视力均较术前下降,其中 9 眼(52.9%)因青光眼进展而下降。
KPro 保留率可接受,仍是高危供体角膜移植失败眼的可行选择。但术后常需行后续手术以处理并发症。青光眼似乎是不可逆视力丧失的主要病因。